{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:11:14Z","timestamp":1765545074319,"version":"3.48.0"},"reference-count":17,"publisher":"BMJ","issue":"6530","license":[{"start":{"date-parts":[[1986,5,10]],"date-time":"1986-05-10T00:00:00Z","timestamp":516067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br Med J (Clin Res Ed)"],"published-print":{"date-parts":[[1986,5,10]]},"abstract":"<jats:p>Eleven patients with Paget's disease treated with sodium etidronate 20 mg\/kg\/day for two and four weeks showed significant reductions in plasma alkaline phosphatase activity and urinary hydroxyproline excretion, both of which are biochemical markers of bone turnover. After four weeks of treatment, however, histological examination of iliac crest biopsy samples showed that despite a rapid reduction in bone resorption there was an appreciable mineralisation defect; even after only two weeks' treatment the abnormalities in bone formation persisted for up to 10 weeks. The adverse effects of sodium etidronate on mineralisation cannot be dissociated from its beneficial effect on resorption even when it is given for short periods.<\/jats:p>","DOI":"10.1136\/bmj.292.6530.1227","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T15:19:55Z","timestamp":1238685595000},"page":"1227-1229","source":"Crossref","is-referenced-by-count":60,"title":["Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate."],"prefix":"10.1136","volume":"292","author":[{"given":"C J","family":"Gibbs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J E","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1986,5,10]]},"reference":[{"key":"ref_1","first-page":"235","article-title":"Paget's disease of bone","volume":"42","author":"Smith, R.; Russell, R.G.G.; Bishop, M.C.; Woods, C.G.; Bishop, M.","year":"1973","unstructured":"Smith R, Russell RGG, Bishop MC, Woods CG, Bishop M. Paget's disease of bone. Q J Med 1973;42:235-56.","journal-title":"Q J Med"},{"key":"ref_2","first-page":"894","article-title":"Diphosphonates in Paget's disease","volume":"i:","author":"Russell, R.G.G.; Smith, R.; Preston, C.; Walton, R.J.; Woods, C.G.","year":"1974","unstructured":"Russell RGG, Smith R, Preston C, Walton RJ, Woods CG. Diphosphonates in Paget's disease. Lancet 1974;i:894-8.","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF02064099","article-title":"Quantitative bone histology in Paget's disease ofbone: influence of sodium etidronate (EHDP) therapy","volume":"22","author":"Khairi, M.R.A.; Meunier, P.; Edouard, C.","year":"1977","unstructured":"Khairi MRA, Meunier P, Edouard C, et al. Quantitative bone histology in Paget's disease ofbone: influence of sodium etidronate (EHDP) therapy. Caicilled Tissue Research 1977;22(suppl): 355-8.","journal-title":"Caicilled Tissue Research"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-87-6-656","article-title":"Sodium etidronate in the treatment of Paget's disease of bone","volume":"87","author":"Khairi, M.R.A.; Altman, M.D.; DeRosa, G.P.; Zimmerman, J.; Schenk, R.K.; Johnston, C.C.","year":"1977","unstructured":"Khairi MRA, Altman MD, DeRosa GP, Zimmerman J, Schenk RK, Johnston CC. Sodium etidronate in the treatment of Paget's disease of bone. Ans Intem Med 1977;87:656-63.","journal-title":"Ans Intem Med"},{"key":"ref_5","first-page":"821","article-title":"Focal osteomalacia due to lowdose diphosphonate therapy in Paget's disease","volume":"i:","author":"Boyce, B.F.; Smith, L.; Fogelman, I.; Johnston, E.; Ralston, S.; Boyce, I.T.","year":"1984","unstructured":"Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyce IT. Focal osteomalacia due to lowdose diphosphonate therapy in Paget's disease. Lancet 1984;i:821-4.","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0221-8747(81)90036-9","article-title":"Paget's disease ofbone: diagnosis and management","volume":"3","author":"Kanis, J.A.; Evanson, J.M.; Russell, R.G.G.","year":"1981","unstructured":"Kanis JA, Evanson JM, Russell RGG. Paget's disease ofbone: diagnosis and management. Metab Bone Dis RelatRes 1981;3:219-30.","journal-title":"Metab Bone Dis RelatRes"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/jcp.35.8.807","article-title":"Measurement ofthe fasting uinary hydroxyproline:creatinine ratio in normal adults and its variation with age and sex","volume":"35","author":"Hodgkinson, A.; Thompson, T.","year":"1982","unstructured":"Hodgkinson A, Thompson T. Measurement ofthe fasting uinary hydroxyproline:creatinine ratio in normal adults and its variation with age and sex.J Clin Pathol 1982;35:807-1 1.","journal-title":"J Clin Pathol"},{"key":"ref_8","first-page":"239","article-title":"Purification of plasma vitamin D metabolites for radioimmunoassay","volume":"108","author":"Taylor, G.A.; Peacock, M.; Pelc, B.; Brown, W.; Holmes, A.","year":"1980","unstructured":"Taylor GA, Peacock M, Pelc B, Brown W, Holmes A. Purification of plasma vitamin D metabolites for radioimmunoassay. Clinica ChinicaActa 1980;108:239-46.","journal-title":"Clinica ChinicaActa"},{"issue":"32","key":"ref_9","first-page":"1251","article-title":"Staining ofthe calcification front in human bone, using contrasting fluorochromes in vitro","volume":"1984","author":"Aaron, J.E.; Makins, N.B.; Francis, R.M.; Peacock, M.","unstructured":"Aaron JE, Makins NB, Francis RM, Peacock M. Staining ofthe calcification front in human bone, using contrasting fluorochromes in vitro.J Histochem Cytochem 1984,32:1251-61.","journal-title":"J Histochem Cytochem"},{"key":"ref_10","first-page":"564","article-title":"Histological methods","volume-title":"phosphate andmagnesiwn metabolism","author":"Aaron, J.","year":"1976","unstructured":"Aaron J. Histological methods. In: Nordin BEC, ed. Cakcium phosphate andmagnesiwn metabolism. Edinburgh: Churchill Livingstone, 1976:564-8."},{"key":"ref_11","first-page":"45","article-title":"Changes in renal and extrarenal handling of phosphate induced by sodium etidronate (EHDP) in man","volume":"49","author":"Walton, R.J.; Russell, R.G.G.; Smith, R.","year":"1975","unstructured":"Walton RJ, Russell RGG, Smith R. Changes in renal and extrarenal handling of phosphate induced by sodium etidronate (EHDP) in man. Clincal Science and Molecular Medicine 1975;49:45-56.","journal-title":"Clincal Science and Molecular Medicine"},{"key":"ref_12","first-page":"79","article-title":"Effective short term treatment ofPaget's disease with oral etidronate","volume":"292","author":"Preston, C.J.; Yates, A.J.P.; Beneton, M.N.C.; etal","year":"1986","unstructured":"Preston CJ, Yates AJP, Beneton MNC, etal. Effective short term treatment ofPaget's disease with oral etidronate. BrMedJ7 1986;292:79-80."},{"key":"ref_13","first-page":"301","article-title":"Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy","volume":"3","author":"Siris, E.S.; Canfield, R.E.; Jacobs, T.P.; Stoddard, K.E.; Spector, P.J.","year":"1981","unstructured":"Siris ES, Canfield RE, Jacobs TP, Stoddard KE, Spector PJ. Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy. MesabBoneDisRelasRes 1981;3:301-8.","journal-title":"MesabBoneDisRelasRes"},{"key":"ref_14","first-page":"247","article-title":"Influence of a diphosphonate on the cellular aspect of young bone tissue","volume":"32","author":"Plasmans, C.M.T.; Jap, P.H.K.; Kuigars, W.; Stoof, T.J.J.H.","year":"1980","unstructured":"Plasmans CMT, Jap PHK, Kuigars W, Stoof TJJH. Influence of a diphosphonate on the cellular aspect of young bone tissue. CalcifTisseIn 1980;32:247-56.","journal-title":"CalcifTisseIn"},{"author":"Accepted 4 March 1986)","key":"ref_15","unstructured":"(Accepted 4 March 1986)"},{"key":"ref_16","article-title":"Wilson showed that plasma and urinary thiocyanate concentrations were lower in a group of smokers with Leber's hereditary optic neuropathy than in a control group without this neuropathy.' This and the finding of raised plasma cyanocobalamin concentrations in these patients' led to the hypothesis that there is an inborn error in cyanide detoxication in patients with Leber's hereditary optic neuropathy.\"","author":"In","year":"1965","unstructured":"In 1965 Wilson showed that plasma and urinary thiocyanate concentrations were lower in a group of smokers with Leber's hereditary optic neuropathy than in a control group without this neuropathy.' This and the finding of raised plasma cyanocobalamin concentrations in these patients' led to the hypothesis that there is an inborn error in cyanide detoxication in patients with Leber's hereditary optic neuropathy.\" Another hypothesis is that Leber's Departments of Neurology, Medical Ophthalmology, and Chemical Patholoagy, St Thomas's Hospital, London SEI 7EH","journal-title":"Another hypothesis is that Leber's Departments of Neurology, Medical Ophthalmology, and Chemical Patholoagy"},{"key":"ref_17","article-title":"The main detoxication route for cyanide is the enzymic transfer of sulphur from thiosulphate (or mercaptopyruvate) to cyanide to form thiocyanate. Wilson found no difference in the activity of thiosulphate sulphurtransferase (rhodanese; EC 2.8.1.1) in liver samples taken at necropsy of two patients who had had Leber's hereditary optic neuropathy compared with samples from controls.'","year":"1981","unstructured":"The main detoxication route for cyanide is the enzymic transfer of sulphur from thiosulphate (or mercaptopyruvate) to cyanide to form thiocyanate. Wilson found no difference in the activity of thiosulphate sulphurtransferase (rhodanese; EC 2.8.1.1) in liver samples taken at necropsy of two patients who had had Leber's hereditary optic neuropathy compared with samples from controls.' In 1981, however, Cagianut et al reported reduced activity of liver rhodanese in two patients with Leber's hereditary optic neuropathy compared with living and dead controls.5","journal-title":"In; Cagianut et al reported reduced activity of liver rhodanese in two patients with Leber's hereditary optic neuropathy compared with living and dead controls.5"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.292.6530.1227","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.292.6530.1227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:00:18Z","timestamp":1765544418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.292.6530.1227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,5,10]]},"references-count":17,"journal-issue":{"issue":"6530","published-online":{"date-parts":[[1986,5,10]]},"published-print":{"date-parts":[[1986,5,10]]}},"alternative-id":["10.1136\/bmj.292.6530.1227"],"URL":"https:\/\/doi.org\/10.1136\/bmj.292.6530.1227","relation":{},"ISSN":["0267-0623","1468-5833"],"issn-type":[{"type":"print","value":"0267-0623"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1986,5,10]]}}}